ArticleFrontiers in cell and developmental biology2026
Mechanism of luteolin in treating chronic heart failure by regulating HIF-1 signaling pathway-mediated mitochondrial damage to inhibit cardiomyocyte apoptosis.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic heart failure (CHF) is a systemic cardiovascular disease characterized by an extremely poor prognosis. Luteolin demonstrates promising therapeutic potential in the prevention and management of CHF. This study aims to explore the mechanism by which luteolin ameliorates CHF through mitigating mitochondrial damage and inhibiting cardiomyocyte apoptosis, using bioinformatics analysis combined with Methods: Network pharmacology was employed to identify functional targets of luteolin, as well as target genes associated with CHF and mitochondrial damage. The overlapping targets from the three datasets were obtained to construct a protein-protein interaction (PPI) network. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses, followed by molecular docking, were then conducted. Bioinformatic approaches were utilized to screen potential signature genes from the PPI network to build a clinical prediction model. Single-cell transcriptomics (scRNA-seq) was performed to characterize the expression profiles of these signature genes in cardiomyocyte subpopulations. Lastly, the results were comprehensively validated by Results: In total, 329 overlapping targets of luteolin, mitochondrial damage and CHF were obtained; 122 core targets with above-average degree values were mainly enriched in the HIF-1 pathway. Six signature genes (HIF1A, NOS2, BNIP3, BNIP3L, PDK1, and BBC3; collectively termed the L-M-C gene set) were identified through 113 machine-learning combinations. The six-gene clinical model demonstrated favorable predictive performance. scRNA-seq demonstrated progressive upregulation of L-M-C genes during the transition from normal to injured cardiomyocytes in CHF. Conclusion: Luteolin exerts therapeutic effects against CHF by inhibiting the HIF-1 signaling pathway and downregulating the expression of target genes such as NOS2 and BNIP3. This regulatory action attenuates myocardial mitochondrial damage and fibrosis, thereby ameliorating the pathological structural remodeling of the myocardium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.